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Abstract Reviewing the past and the present status of 
personalized medicine, the hope and promise from several 
years ago was critically compared to what is really achieved 
to tailor the drug treatment according to the patient’s in-
dividuality. The basis for consideration is what we know 
about the variant of the disease the patient is suffering 
from, and about the mechanisms influencing the plasma 
concentration-time profile, such as activity of metaboliz-
ing enzymes and transporters. In cancer treatment, drugs 
are currently selected regarding molecular properties of 
the cancer tissue, eg, expressing receptors such as HER2 
receptor. Currently diagnostic tests are available allowing 
to detect somatic cell mutations that can be used to guide 
drug selection. Unfortunately, tumor heterogeneity and 
developing resistance by further mutations may limit the 
success of the therapy determined by molecular diagnos-
tics. The present status can be described that in drug ki-
netics we know the influencing factors and we understand 
the mechanisms. However, only in a few cases the genetic 
background is the main determinant of kinetic variability, 
and environmental and other factors have an additional 
important role. Therefore, much more has to be done be-
fore we can translate the accumulating knowledge into a 
benefit for the patient. Only then, we can speak about per-
sonalized medicine.
WhAt iS peRSonAlizeD meDicine?
Personalized medicine is an expression embracing ideas 
and a concept of making the treatment of a patient as in-
dividualized as possible. The therapy should be guided 
by clinical, genetic, genomic, and environmental in-
formation, which is different for every patient. The data of-
fered are about the underlying mechanisms of the patient’s 
disease, and can be used for drug selection (“selecting the 
right drug”) or to determine the appropriate dose (“selecting 
the right dose”). The individual response to drugs depends 
not only on the mechanisms of the disease (pharmacody-
namics), but in addition on the handling of the drug by the 
patient (pharmacokinetics).
In 2002, the successful sequencing of the human genome 
was greeted with much enthusiasm. It was announced 
that the era of molecular medicine has begun and scien-
tists and some physicians were promising that the field 
of personalized medicine would come at a fast pace. The 
hopes of many patients, which the high flying promises 
have provoked have still to be fulfilled. In addition, it is to 
be noted that this progress will not come without costs in 
the health care system and that there are financial inter-
ests intertwined with the science and with the good inten-
tions to provide the patients with the best medical care 
they deserve.
Personalized medicine also encompasses the manage-
ment of patients’ personal data and medical informa-
tion by information and communication technology 
(ICT) (1,2). It should however be noticed that frequently 
the medical doctors and patients are reluctant to make 
this information available on ITC platforms because of 
fear that the data could leak into the public domain. In 
some countries, there may be unwanted corollaries if the 
information is available with respect to employment and 
health insurance. Hence, the progress might come with 
some expenses that have to be weighed against the ben-
efits it brings with it.
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hoW it StARteD –phARmAcoKinetic oBSeRVAtionS 
WeRe FiRSt
In the 1950s, it was clinically observed that patients dif-
fered concerning their reactions toward drugs, including 
the side effects. The first description of an inherited defect 
concerned the muscle relaxant succinylcholine. The dura-
tion of this drug’s action is determined by hydrolysis. Sub-
jects homozygous for a gene encoding an atypical form 
of the enzyme mediating the hydrolysis have a prolonged 
drug-induced muscle paralysis. At this time, clinical obser-
vation and family tree investigation built the tool to identi-
fy inheritance. The tuberculostatic isoniazid is metabolized 
by N-acetylation. It became obvious that side effects were 
related to prolonged half-life and it was identified that the 
defect in N-acetylation activity was hereditary. The same 
pattern could be described for the antihypertensive drug 
hydralazine and the antiarrythmic drug procainamide (3,4). 
In the mid 1970s, findings of a new drug metabolizing en-
zyme defect drew the attention toward hydroxylation of 
drugs (5-7). Later, it was found out that hydroxylation of 
drugs was mediated by the cytochrome P450 enzyme 
(CYP) system, the most important system in terms of drug 
metabolism in humans. The molecular basis for the ob-
served defects was only elucidated at the end of the 1980s 
by Gonzales et al (8) and Kimura et al (9), showing that the 
phenotype of poor metabolizer was characterized by mu-
tant alleles leading to lacking or inactive enzyme. The mu-
tations differed in patients with the same phenotype. The 
clinical importance of the findings and their implications 
for drug development was discussed at this time. It was 
obvious that clinically relevant changes of drug response 
and possible side effects were expected only with drugs 
having a steep concentration-response relationship and/
or a narrow therapeutic window (10). The prevalence of the 
slow metabolizer phenotype of the debrisoquine type was 
determined to be 7.40% in the European population based 
on 8764 determinations, consistent with a gene frequency 
of 0.27. The debrisoquine phenotype was later attributed 
to the gene regulating the expression of cytochrome (CYP) 
2 D6. The overall mean of the phenotype of slow metabo-
lizers of mephenytoin was 3.52%, corresponding to a gene 
frequency of 0.19 (11). The phenotype was later attributed 
to CYP 2C19. These data show that the polymorphism of 
hydroxylation is based on the prevalence and the gene fre-
quency in the population. It later became obvious that not 
only gene defects with an impaired function are present in 
the population but also gene duplications with the con-
sequence of an enhanced metabolic capacity. The conse-
quences for dosing are obvious: in patients with inactive 
enzyme (“poor metabolizers”) the dose of the drug must 
be reduced and in patients with gene amplification and 
enhanced metabolic capacity (“ultrarapid metabolizers”) 
the dose must be increased (12).
WhAt iS the pReSent StAtUS in phARmAcoKineticS?
Presently, in the therapeutic reality there are only few ex-
amples that demonstrate a clear correlation between ther-
apeutic outcome and metabolic capacity. In a study of 
psychiatric patients treated with the antidepressant ven-
lafaxine ultra rapid, extensive, intermediate, and poor me-
tabolizers of CYP2D6 were identified. Poor metabolizers 
had more side effects in comparison with other patients 
(P < 0.005), still the therapeutic efficacy did not significant-
ly differ between the different phenotypes (13). The poor 
predictivity of therapeutic outcome guided by only one 
factor, namely activity of the metabolizing enzyme, points 
to the fact that the variability in metabolism and drug re-
sponse is due to multiple factors that contribute to the ob-
served variability. One single factor explains only a certain 
part of the total variability. Hence, the approach of iden-
tifying several factors/markers is better suited to explain 
variability. One recent example is given by Sistonen et al 
(14), who identified genetic markers predictive of central 
nervous system depression in 111 breastfeeding mothers 
using codeine and their infants. A genetic model combin-
ing the maternal genotypes of CYP2D6 and ABCB1 trans-
porter predicted 87% of the infant and maternal central 
nervous system depression cases with a sensitivity of 80% 
and a specificity of 87%. In addition, the anticoagulant 
drug warfarin is a further example. It is widely prescribed 
for therapeutic anticoagulation. Patients vary widely (20-
fold) in the dose needed to achieve an appropriate level of 
coagulation parameters to prevent either too low (risking 
under-treatment) or too high doses (risking severe bleed-
ing). In a genome-wide association study, Takeuchi et al 
(15) confirmed that two genes (VKORC1, CYP2C9) explained 
about 40% of the variability in warfarin dose. They discov-
ered a new gene (CYP4F2) contributing to 1%-2% of the 
variability. Unfortunately, clinical trials assessing patient 
benefit from individualized dose forecasting based on the 
patient’s genetic makeup at VKORC1, CYP2C9, and CYP4F2 
have not yet provided sufficient evidence to support the 
use of pharmacogenetics to guide warfarin therapy (16). 
Only the time to achieve appropriate anticoagulation was 
shorter when dosing was guided by CYP 2C9 genotyping 
(17). Further clinical trials are needed to define how war-
farin pharmacogenetics could contribute to a better 
dosing in clinical practice. The rather confusing sit-
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uation with clopidogrel, an antiplatelet acting substance, 
has been elucidated by Johnson et al (18). Clopidogrel is a 
prodrug that needs activation by CYP2C19 dependent me-
tabolism. Carriers of the CYP2C19 *2 allele (heterozygotes 
and homozygotes) have lower active metabolite plasma 
concentrations and less antiplatelet effect. Johnson et al 
(18) analyzed available studies and came to the conclusion 
based on their analysis of the patients for whom clopi-
dogrel provides the greatest benefit: namely, patients af-
ter percutaneous coronary intervention, which includes 
stenting, do also profit from CYP2C19 genotyping prior to 
dosing. In patients treated for other indications, the clini-
cal benefit was independent from the metabolizer status. 
Harmze et al (19) modified this view looking at side effects. 
They found that patients with the CYP2C19*1/*17 and 
*17/*17 diplotype had an increased risk of major bleeding 
events after coronary stenting than patients with the *1/*1, 
the “wild” genotype. Testing before treatment with clopi-
dogrel to identify the appropriate individual dose is recom-
mended by American Food and Drug Administration (FDA) 
but not by the European Medical Agency (EMA) (20).
SiDe eFFectS oF DRUGS AnD Genetic mARKeRS
It has been known for a long time that the genetic dis-
position is important for the development of side effects 
of drugs (21,22). Liver injury is one of the most important 
side effects because it is severe and even life threatening. 
In genome-wide association studies, the human leukocyte 
antigen (HLA) system has been identified to play a role in 
eliciting major and clinically important side effects. Un-
til now, the knowledge on the genetic basis of the drugs’ 
side effect has only partially transformed into the clinical 
handling of these drugs. For example, testing is required 
before abacavir is given to a patient (20). However, testing 
before prescribing was not required for other drugs until 
now, although the information is mentioned in the drugs’ 
information sheet (so-called labeling) at least for drugs ap-
proved by FDA.
WhAt iS the StAtUS in phARmAcoDYnAmicS?
The effects of drugs vary widely among a population. This 
is not only because of variability in the kinetics of the drug 
but also because of the underlying mechanism responsi-
ble for the disease that may be different irrespective of the 
identical phenotype. It should be noted that disease may 
be due to mutations in the germ cell line and potential 
factors for hypertension may be one of the examples. 
In cancer, however, the mutations may concern not 
the germ cell but the somatic cell line, for example in colo-
rectal carcinoma (CRC). We address here two major thera-
peutic fields, cardiovascular diseases and cancer, to explore 
the contribution of genome analysis in the selection of the 
appropriate drug for the individual patient.
cardiovascular diseases
Genomics in the cardiovascular field is directed toward un-
derstanding biological mechanisms of diseases and trans-
lating that knowledge to select the appropriate drug for 
the individual. During the past 5 years, hundreds of car-
diovascular loci have been discovered. Genome-wide as-
sociation study has been undertaken by the international 
consortium for blood pressure and it identified in 200 000 
Europeans 29 single-nucleotide polymorphisms (SNPs) at 
28 loci associated with regulation of the blood pressure 
(23). It is understandable that this information is of interest 
for the possible development of new drugs targeting spe-
cific regulation mechanisms. Molecular findings, however, 
have not yet found the way into clinical practice. The Sev-
enth Report of the Joint National Committee on Prevention 
(www.nhlbi.nih.gov/guidelines/hypertension/) discusses 
clinically determined criteria helpful for selecting the ap-
propriate antihypertensive drug, such as concomitant re-
nal insufficiency, diabetes, and left ventricular hypertrophy. 
Currently only phenotypic factors but no genotypic factors 
influence the selection of antihypertensive drugs for the 
individual patient.
Pharmacogenomics might explain the variation in drug ef-
ficacy and more consideration needs to be given to the 
clinical context to define where pharmacogenomics would 
be an additional tool to monitor or predict therapeutic suc-
cess (24). As, at present, the place of pharmacogenomics in 
cardiovascular medicine is not defined, further studies are 
needed recruiting tens of thousands of patients with car-
diovascular disease that combine tests of genome-wide 
association with sequencing. The genomic studies have to 
be supplemented by functional studies aimed to charac-
terize molecular and cellular pathways. It should also be 
noted that there is more than the genome that influences 
treatment outcome, namely clinical, biological, or environ-
mental factors that have to be meaningfully integrated to 
support personalized decision making in cardiology (25).
cancer
The field of oncology is the area in medicine where ge-
nomic data and information is used on a daily basis. Here 
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we can present several well established examples of the 
advantage of its use in identifying somatic mutations in 
the genotype of the tumor that are strong determinants 
of drug response.
Breast cancer. The HER2 (also called ErbB-2) receptor be-
longs to the epidermal growth factor receptor family of 
receptors characterized by an extracellular ligand binding 
domain, a transmembrane domain, and an intracellular 
domain. Epidermal growth factor receptors have an activ-
ity as plasma membrane-bound receptor tyrosine kinases. 
Their intracellular domain can interact with a multitude of 
signaling molecules in the cell. Signaling through HER2 or 
other members of the receptor family promotes cell prolif-
eration and opposes cell death by apoptosis. In normal life, 
signaling through this pathway is tightly regulated to pre-
vent uncontrolled cell growth. Amplification of the gene 
regulating the receptor protein or gene overexpression 
is seen in 15%-20% of breast cancers. Gene amplification 
or overexpression is a prognostic marker and indicates a 
poor outcome of the disease (26). During the past decade, 
treatment, specifically targeted at HER2, has improved 
disease-free survival in patients with breast cancers that 
overexpress HER2 but it has not convincingly increased 
the overall survival (27). Nevertheless testing is necessary, 
before treatment is initiated, in order to predict whether 
drugs directed toward HER2 will have a chance to be effec-
tive or whether the treatment will only cause side effects.
Very recently it has been demonstrated that acting on the 
same target by adding pertuzumab to a treatment with 
trastuzumab and docetaxel does improve progression-free 
survival in patients with HER2 positive metastatic breast 
cancer (control median: 12.4-month; addition of pertuzum-
ab 18.5-month). However, the positive influence on overall 
survival of the patients is still to be documented (28).
Colo-rectal cancer. Another example where diagnostic test-
ing is used is the anticancer therapy directed toward epi-
dermal growth factor receptor (EGFR). Similar to HER2, the 
EGFR receptor is on the surface of cancer cells. Monoclonal 
antibodies have been approved to treat EGFR-expressing 
late-stage colorectal cancer (CRC) in patients who had be-
come resistant to chemotherapy. It has been found out that 
the drug is not effective in patients whose tumors have a 
mutated KRAS gene, which is associated with resistance 
to drugs that are anti-epidermal growth factor receptor 
(EGFR) antibodies. The tumors of patients with metastatic 
colorectal cancer are now profiled for seven KRAS muta-
tions before receiving monoclonal antibodies. Polymerase 
chain reaction-based kits (eg, Therascreen, Quiagen) can 
provide information about the KRAS gene mutation in pa-
tients whose CRC has metastasized. These tests have been 
approved recently by FDA to determine if the absence of a 
gene mutation would indicate the treatment with a mono-
clonal antibody. In one clinical study with cetuximab, in pa-
tients whose tumors did not have a KRAS mutation, me-
dian survival was 8.6 months compared with 5 months in 
the control group. In patients with a KRAS mutation, me-
dian survival was similar in those who received the drug as 
in the control group (4.8 months and 4.6 months, respec-
tively). Hence, testing is helpful for predicting the outcome. 
However, we have to admit that we still wait for therapeutic 
breakthroughs as even in the most favorable case surviv-
al was prolonged for a few months only. In a recent study, 
other mutations, namely BRAF, NRAS, and PIK3CA exon 20 
mutations, were also found to be associated with a low re-
sponse rate. From this study, it can be concluded that addi-
tional genotyping of BRAF, NRAS, and PIK3CA exon 20 mu-
tations in a KRAS wild-type population may help to identify 
patients with a good therapeutic outcome (29).
AppRoVAl oF teStS toGetheR With the DRUG
Two further tests to increase the prediction of tumor re-
sponse were approved. Anaplastic lymphoma kinase (ALK) 
is the genetic basis for a receptor tyrosine kinase involved 
in cell growth regulation. Rearrangement in this gene 
(ALK+) has a role in the oncogenesis of non-small cell lung 
carcinomas (NSCLs), especially adenocarcinomas. The ALK 
inhibitor crizotinib was approved in August 2011 by the 
FDA for treating late-stage NSCLCs that are ALK+ together 
with the diagnostic test to enable appropriate “individual-
ized” therapy. However, meanwhile acquired crizotinib re-
sistance in ALK+ non-small cell lung carcinomas was ob-
served (30).
Another key finding, which explains the limited success of 
individualized therapy besides acquired resistance, is that 
different regions of the tumor have different mutations. 
Single tumor-biopsy samples can therefore lead to under-
estimate intra-tumor heterogeneity. Tumor heterogeneity 
may enhance adaptation of the tumor through Darwin-
ian selection and lead to therapeutic failure. In addition, 
alterations of the genes by epigenetic mechanisms and 
further changes in signal transduction may be important 
for the survival of the tumor. Based on these findings and 
results we have to admit that the concept of directing 
therapy based on genetic tumor markers is probably 
too simple.
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The lesson to be learned is that genetic changes have to 
be expected within some months of therapy. If we can 
identify the genes that are affected by Darwinian selection 
we could be able to make them targets for drug develop-
ment (31,32).
WhAt iS the peRSpectiVe?
on the scientific level
In 2002, the human genome project was completed. Since 
that time, the techniques used in genomics have tremen-
dously progressed. Methodological advances in statistics 
have yielded hundreds of confirmed associations between 
genes and disease. We expect that improvements in “next 
generation” sequencing will soon be available, making it 
feasible that people will be able to carry their genome on a 
memory stick. However, at present it is yet unclear whether 
anyone would want to do so.
Obviously, the present approaches are conceptually too 
simple to cover the biological reality. The human nuclear 
genome is only apparently a simple construct since it con-
tains 3.2 billion nucleotides. A complex system guides ac-
cess to the double-stranded DNA by regulating synthesis 
and gene expression in response to internal and external 
stimuli. Variability and susceptibility is not only determined 
by DNA sequence variants (DSVs) but by mechanisms that 
govern the expression of a phenotype, such as histone 
modifications, microRNAs, long noncoding RNAs, epige-
netics, splice variants, and posttranslational modifications 
of the encoded proteins. At present, we only partially un-
derstand how the environmental factors come into the 
play as the mechanisms of epigenetic modifications were 
unfolded (32,33). Furthermore, gene-gene interactions 
were overlooked in the past because of the computational 
burden of interactions assessment, and it is still not in the 
focus of genome-wide association studies (34).
Thus, a complex phenotype of an individual is the conse-
quence of complex interactions of a large number of ge-
netic and non-genetic determining factors, which we cur-
rently are not able to decipher.
The scientific committee of the National Cancer Institute in 
the US has recently given recommendations to accelerate 
translation from basic science into the clinical application. 
The recommendations are directed toward gaining more 
knowledge on the relationship between germ line ge-
netic make-up, somatic genetic changes, pheno-
type, and features related to cancer treatment response 
and adverse events (35).
on the level of dissemination
In order that personalized medicine can be used effective-
ly by health care providers, and the patients, the findings 
in the field must be translated into information when the 
diagnostic tests and targeted therapies are right in place. 
This information is given occasionally, eg, in testing pa-
tients genetically to determine their likelihood of having a 
serious adverse reaction to various cancer drugs. The infor-
mation on genetic markers for drug and dose selection in 
the drug data sheet is provided by FDA.
However, the results of a recent study in the US (36) in-
dicate that even physicians feel not well informed about 
the clinical value, availability, and interpretation of pharma-
cogenomic tests. A recent survey of surgeons in the United 
Kingdom found, worryingly, that only half of patients with 
invasive cancer had a HER2 result available when treat-
ment was initially discussed (37). The findings highlight the 
need for a more effective physician education and better 
information of the administration responsible for manag-
ing to timely provide the testing results.
Unfortunately, most information dissemination found on 
the internet expresses high flying promises. It would be 
better to provide information on what we know and what 
we do not know yet and what benefit a patient really can 
expect for what cost.
conclUSion
The molecular basis of variability in effective drug doses 
was understood several decades ago. Understanding, 
however, does not transfer automatically in therapeutically 
important improvements. Whereas the concept of testing 
for molecular changes to explain metabolic differences is 
accepted, we have to note that the clinical influence of a 
changed metabolism is modest in most of the cases. So-
matic mutations are important for detecting whether the 
patient will respond to new drugs targeted for tumor spe-
cific molecular features. Success is limited by tumor het-
erogeneity, which is not easily detected and by develop-
ment of tumor cell resistance at the molecular and cellular 
level. There is a long way to go to fight these obstacles. The 
concept of personalized medicine is intellectually attrac-
tive and scientists are convinced that this is the way for-
ward. However, dissemination of the current status instead 
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of unrealistic promises will be a cornerstone for the accep-
tance by doctors and patients alike.
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